Dermata Therapeutics, Inc. (DRMA) stock
Close on Nov 13, 2026Market cap $2.50MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $2.50M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.64
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$9.50M
- EPS, diluted
- -$3.42
- Book value per share
- $0.76
- Diluted shares
- 5M
Trading
- Next earnings
- Mar 25, 2027 (estimated, after the close)
- Previous close
- $0.66
- Open
- $0.66
- Day's range
- $0.57 – $0.67
- Volume
- 160,686
- Average volume (20 days)
- 148,208
- Beta (5 years)
- 1.28
- 52-week range
- $0.57 – $4.66
- RSI (14 days)
- 33.3
- Volatility (1 year)
- 131.9%
- Relative volume
- 0.07×
- WACC
- 11.5%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | DRMA | S&P 500 | Difference | DRMA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -27.8% | -3.0% | −24.7 pts | ||
| 3 months | -60.4% | -2.8% | −57.7 pts | ||
| Year to date | -73.2% | +11.5% | −84.7 pts | ||
| 1 year | -80.2% | +13.5% | −93.7 pts | ||
| 3 years | -99.4% | +77.7% | −177.1 pts | -81.6% | +21.1% |
| 5 years | -100.0% | +72.6% | −172.6 pts | -86.1% | +11.5% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Dermata Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Results
- Results
- News
About Dermata Therapeutics
Pharmaceutical Preparations
Dermata Therapeutics, Inc. is a scientific skincare company focused on developing and commercializing treatments for common and underserved dermatological conditions, such as acne. The company is shifting its strategic focus from prescription pharmaceuticals toward science-backed, direct-to-consumer and professional business-to-business skincare lines, branded as Tome. Its planned product portfolio includes foundational topical treatments and over-the-counter acne systems utilizing a purified freshwater sponge powder known as Spongilla lacustris, or Bioneedle, combined with active ingredients like salicylic acid. Beyond topical acne solutions, the company explores applications for its microstructure technology to facilitate intradermal delivery of aesthetic treatments.
Company profile, executives and historyDermata Therapeutics stock: common questions
What is Dermata Therapeutics's stock price?
DRMA closed at $0.62 on Nov 13, 2026, down 6.01% on the day. Over the past 52 weeks it traded between $0.57 and $4.66.
What is Dermata Therapeutics's market cap?
Dermata Therapeutics was worth $2.50M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is DRMA's P/E ratio?
Dermata Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.42), so it has no meaningful P/E ratio.
Does Dermata Therapeutics pay a dividend?
No. Dermata Therapeutics has not paid a cash dividend over the last twelve months.
When does Dermata Therapeutics report earnings next?
Dermata Therapeutics is expected to report Q4 FY2026 results on Mar 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has DRMA stock performed over the past year?
Including dividends, DRMA returned -80.2% over the past year, against +13.5% for the S&P 500.
How many DRMA shares are sold short?
0M shares were sold short at the latest FINRA report, 3.16% of the float, or 1.0 days of average trading volume.
Who are Dermata Therapeutics's competitors?
Companies most similar to Dermata Therapeutics by business, industry and size include SLGL, ARQT, DERM, SKVI, AZTR.
See a number that looks wrong?